These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31643137)

  • 1. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
    Feng LY; Wada K; Chung H; Han E; Li JH
    Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances in Taiwan: challenges and strategies.
    Feng LY; Li JH
    Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014.
    Feng LY; Yu WJ; Chang WT; Han E; Chung H; Li JH
    Subst Abuse Treat Prev Policy; 2016 Sep; 11(1):34. PubMed ID: 27663984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.
    Yu WJ; Cottler L; Li JH
    J Food Drug Anal; 2021 Mar; 29(1):168-181. PubMed ID: 35696229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of controlled drugs and new psychoactive substances (NPS) regulations in East and Southeast Asia.
    Lin OA; Chuang PJ; Tseng YJ
    Regul Toxicol Pharmacol; 2023 Feb; 138():105338. PubMed ID: 36642324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
    Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
    PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs).
    Smith JP; Sutcliffe OB; Banks CE
    Analyst; 2015 Aug; 140(15):4932-48. PubMed ID: 26031385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the nutrient-based standards for school lunches among South Korea, Japan, and Taiwan.
    Kim M; Abe S; Zhang C; Kim S; Choi J; Hernandez E; Nozue M; Yoon J
    Asia Pac J Clin Nutr; 2017 Jan; 26(1):160-168. PubMed ID: 28049276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence, Diversity, and Control of New Psychoactive Substances: A Global Perspective.
    Tettey JNA; Crean C; Ifeagwu SC; Raithelhuber M
    Handb Exp Pharmacol; 2018; 252():51-67. PubMed ID: 29896655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legal Approaches to New Psychoactive Substances: First Empirical Findings.
    van Amsterdam J; Burgess N; van den Brink W
    Eur Addict Res; 2023; 29(5):363-372. PubMed ID: 37557091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worldwide legislative challenges related to psychoactive drugs.
    Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
    Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complex and constantly evolving public health threat of new psychoactive substances in Italy: addressing the main functions of a national observatory of drugs.
    Graziano S; Zaami S; Tittarelli R; Pichini S; Sciotti M; Berretta P; Busardò FP; Marinelli E; Tini A; Scaravaggi G; Buscaglia E; Brambilla E; Cavallo M; Locatelli CA; Pacifici R; Varì MR
    Ann Ist Super Sanita; 2021; 57(2):144-150. PubMed ID: 34132212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of insomnia on individual health dissatisfaction in Japan, South Korea, and Taiwan.
    Nomura K; Yamaoka K; Nakao M; Yano E
    Sleep; 2005 Oct; 28(10):1328-32. PubMed ID: 16295219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.